Anemia/drug therapy/etiology; Erythropoietin/therapeutic use; Humans; Neoplasms/complications; Predictive Value of Tests; Recombinant Proteins/therapeutic use
Abstract :
[en] BACKGROUND: Since only a portion of anemic patients outside the uremia setting benefit from erythropoietin treatment, a reliable means of predicting potential responders and nonresponders would be very useful. MATERIALS AND METHODS: We retrospectively reviewed the clinical records of 58 patients with refractory anemia associated with various malignant disorders who had been treated with subcutaneous rHuEpo. The starting rHuEpo dose was 375 U/kg/week for 4 weeks, and was increased to 750 U/kg/week for another 4 weeks if no response was observed. Response was defined as a Hb increase > or = 2 g/dL with no need for blood transfusion. We examined the value of various laboratory parameters (baseline levels, 2-week and 4-week changes) as predictors of response. Endogenous erythropoietin production was evaluated by its serum level and erythroid activity was assessed through reticulocyte count and circulating transferrin receptor. RESULTS: Forty-eight individuals were evaluable, 58% of whom responded to rHuEpo within 8 weeks. Multiple regression analysis showed that 53% of the variation in the 8-week Hb concentration was explained by variations in baseline serum erythropoietin and the 2-week change in serum transferrin receptor (p < 0.001). Based on these two parameters, response prediction in individual patients would have resulted in a sensitivity of 96%, a specificity of 79% and an overall accuracy of 88%. In addition, 58% of the variation in the 8-week Hb was explained by variations in the 4-week changes in Hb and reticulocyte count (p < 0.001). Utilizing these latter parameters and baseline serum erythropoietin, response prediction in individual patients would have resulted in a sensitivity of 92%, a specificity of 82% and an overall accuracy of 88%. CONCLUSIONS: This retrospective analysis suggests that response to rHuEpo can be reasonably predicted by pretreatment serum erythropoietin together with early changes in simple laboratory parameters.
Disciplines :
Hematology
Author, co-author :
Cazzola, M.
Ponchio, L.
Pedrotti, C.
Farina, G.
Cerani, P.
Lucotti, C.
Novella, A.
Rovati, A.
Bergamaschi, G.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
Bergström J. New aspects of erythropoietin treatment. J Intern Med 1993; 233:445-62.
Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994; 68:215-23.
Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Guidelines for the use of recombinant human erythropoietin. Haematologica 1994; 79:526-33.
Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79:29-37.
Ponchio L, Beguin Y, Farina G, et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 1992; 77:494-501.
Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067-76.
Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76:2354-9.
Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993; 7:1324-7.
Ludwig H, Fritz E, Leitgeb C, Percherstorfe, M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-63.
Cazzola M, Messinger D, Battistel V, et al. Rrecombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248:378-81.
Wu H, Liu X, Jaemisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59-67.
Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia. Br J Haematol 1995; 89:831-7.
Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M. Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 1994; 79:456-9.
Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993; 82:2010-6.
Beguin Y, Loo M, R'Zik S, et al. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Br J Haematol 1995; 89:17-23.
Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoietin-α) therapy in cancer patients. Blood 1995; 85:1676-8.
Musto P, Modoni S, Alicino G, et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994; 79:493-9.
